Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comorbidity Pattern Among Adults With MS in the United States: A Propensity Score–Matched Study
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-013
To examine comorbidity patterns among adults with MS versus propensity score–matched non-MS controls.
Despite the importance of understanding the comorbidity burden among individuals with MS, no study has been conducted in the United States at the national level to examine patterns of comorbidities among individuals with MS.
This was a retrospective, cross-sectional, matched cohort study using pooled data from the Medical Expenditure Panel Survey (MEPS) (2005–2015). The study sample consisted of adults (age ≥18 years) who did not die during the calendar year and had positive total health care expenditures. Adults with MS were identified using Clinical Classification System code 80 and matched on propensity scores to non-MS controls (1:1) based on age, gender, and race/ethnicity using a greedy matching algorithm (8:1-digit match). Comorbidities were categorized into specific clusters: cardiometabolic (diabetes/heart disease/hypertension), musculoskeletal (arthritis/osteoporosis), psychiatric (anxiety/depression), respiratory (asthma/chronic obstructive pulmonary disease), cancers, and other comorbidities. Chi-squared test was used to compare the distribution of comorbidities between the two groups. All analyses accounted for the complex survey design of MEPS to generate US national-level estimates.
The final study sample consisted of 541 (unweighted) adults in both MS and propensity score–matched non-MS control groups. Adults with MS had significantly higher national-level proportions of anemia (5.5% vs 1.8%), anxiety (17.1% vs 8.5%), arthritis (42.1% vs 30.1%), depression (29.7% vs 13.3%), and osteoporosis (5.7% vs 2.4%) versus matched non-MS controls (all P<0.05). For comorbidity clusters, psychiatric (41.2% vs 19.0%) and musculoskeletal (46.3% vs 31.0%) proportions were greater (P<0.05) among adults with MS versus non-MS matched controls.
Psychiatric and musculoskeletal comorbidities were more prevalent among adults with MS versus matched non-MS controls. Health care providers should manage these comorbidities alongside MS treatment to reduce comorbidity burden and improve health outcomes among individuals with MS.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Kevin Duhrkopf, PharmD (Sanofi) No disclosure on file
Nupur Greene Nupur Greene has nothing to disclose.
Lobat Hashemi No disclosure on file